8-K filing — Lyell Immunopharma, Inc. (LYEL)
Filed: 2026-09-10 AccNo: 0001193125-26-387890 Size: 161 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful
Lyell Immunopharma shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $36 price target.